Graffinity Announces Multitarget Drug Discovery Research Collaboration With Pfizer

30-Nov-2007

Graffinity Pharmaceuticals GmbH announced that it has entered into its second drug discovery collaboration with Pfizer, Inc. Through the collaboration, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening technology for use in screening Pfizer drug targets. The agreement is Graffinity's sixth discovery collaboration since it was established as an independent company in 2006.

Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of novel small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance